Introduction
Tamoxifen (TAM) is a selective receptor modulator and has been used in hormone therapy for the prophylaxis and adjuvant and neoadjuvant treatment in breast cancer. It expresses a potent estrogenic antagonist effect on the estrogen receptor (ER) by competing with estrogen for binding to the ER and preventing cell growth 1 in ER-positive breast cancer patients. Despite the fact that TAM provides significant clinical benefit, interindividual variability in its metabolism and effectiveness has been linked to single submit your manuscript | www.dovepress.com
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Charoenchokthavee et al nucleotide polymorphisms (SNPs) in the genes encoding cytochrome P450 (CYP450) enzymes that are involved in TAM-metabolic pathways. [2] [3] [4] [5] CYP2D6 and CYP3A5 are the main CYP450 enzymes involved in the transformation of TAM from its conventional prodrug form to the active metabolites endoxifen (END) and 4-hydroxy-tamoxifen (4OHT) ( Figure 1) . 1, 6, 7 Several studies have investigated the associations between polymorphisms in these two enzyme encoded genes and the clinical outcomes of breast cancer 3, 5, [8] [9] [10] [11] [12] [13] [14] [15] or the concentration of TAM and its metabolites ( Figure  2 ). 14, [16] [17] [18] [19] However, routine pharmacogenetic testing has not been suggested due to the inconclusive results obtained. 20, 21 These variations may result from differences in genotyping comprehensiveness, the DNA source, and the sample size. Nevertheless, previous studies revealed that the incomplete functional CYP2D6*4 and CYP3A5*3 alleles showed completely reduced enzyme activity, while CYP2D6*10 decreased its encoded enzyme function. 22, 23 The prevalence of these defective alleles was found to differ among racial populations. Thus, CYP2D6*4 was more prevalent in Caucasians than in Asians or Thais and CYP2D6*10 was more frequent in Asians (Table 1) . 8, 14, 16, 24 CYP3A5*3 was the major allele in Caucasians and Asians, while CYP3A5*1 was the major allele in Thai populations (Table 1) . 9, 14, 24 Thai patients with CYP2D6*10/*10 had a lower END level than those patients with CYP2D6*1/*10 and CYP2D6*1/*1 (P=0.045) 16 and had a shorter disease-free survival than heterozygous CYP2D6*10 or other genotypes (P=0.046). 8 Previous studies have revealed the relationships between these gene polymorphisms and the clinical outcomes in Thai breast cancer patients. 8, 9, 16 These results emphasize the opportunity to improve the pharmacological effectiveness of TAM, which is the most prescribed antihormone therapy for breast cancer treatment in Thailand. However, these studies were limited by their small sample sizes. The main objective of the present study was to determine the prevalence of the CYP2D6*2, real-time PCR and Vii7 software (Thermo Fisher Scientific, Waltham, MA, USA). The PCR thermal cycling was performed as follows: 60°C for 30 seconds and 95°C for 10 minutes, and then, 40 cycles of 95°C for 15 seconds and 60°C for 1 minute before a final 60°C for 30 seconds. The rs numbers of CYP2D6*2, CYP2D6*10, and CYP3A5*3 were rs16947 (2850C>T), rs1065852 (100C>T), and rs776746 (6986A>G), respectively. CYP2D6*4 was determined by considering the haplotype of CYP2D6*2 (2850C>T) with CYP2D6*10 (100C>T). Phenotypes were classified as extensive metabolizer (EM) for normal enzyme activity and intermediate metabolizer (IM) and poor metabolizer (PM) for decreased and completely reduced enzyme activities, respectively (Table 2) . 22 Data analysis was conducted by descriptive statistics using the SPSS software (Version 22; IBM Corporation, Armonk, NY, USA).
Results
A total of 134 Thai breast cancer women undergoing TAM treatment formed the study group. Most of them were in the early stage of breast cancer (32.8% and 43.3% in stages I and II, respectively). Their mean age, weight, and BMI were 51.6±11.6 years (range 27.0-82.0 years), 60.0±10.7 kg (range 36.0-107.5 kg), and 24.0±4.3 (range 15.4-40.0), respectively. Their ER and progesterone receptor (PR) statuses were ER+/PR+ (71.6%), ER+/PR-(26.9%), ER-/PR+ (0.75%), and ER-/PR-(0.75%). The proportion of premenopausal patients (53%) was higher than the postmenopausal (36.6%) ones in this study group. Some patients had been treated with other breast cancer treatments before they received TAM, while nine patients (6.7%) had Moreover, the prevalence of the CYP2D6 phenotype was 41.0%, 57.5%, and 1.5% in the EM, IM, and PM enzyme activity categories, respectively, while the prevalence of the CYP3A5 phenotype was 61.2% and 38.8% for EM and PM, respectively. Note that CYP3A5-IM was not found in this study (Table 4) . Furthermore, only 31 patients (23.1%) were categorized as EM for both the CYP2D6 and CYP3A5 genes, while the others (75.37%) were IM or PM for at least one gene, including the two patients (1.5%) who were PM for both the CYP2D6 and CYP3A5 genes (Table 5 and Figure 3 ).
Discussion
Prevalence of wild-type and mutant alleles including their genotypes was different depending on the racial origin of population (Table 1) . However, the prevalence of these alleles was also different within the same population among studies. First, that the 9.7% frequency of the CYP2D6*1/*1 allele in Thai breast cancer patients found in this research is lower than the prevalence previously reported 16 is probably 25 The prevalence of CYP2D6*1/*1 that was reported in these studies, therefore, depended on the number and position of SNPs that were included in each respective analytical platform, which varied among the three studies. Second, the higher prevalence of CYP2D6*10/*10 found in this study compared with previous studies in Thai breast cancer patients might be due to the larger number of patients who were recruited in this study. More patients helped identifying rare genotypes (CYP2D6*4/*4 and CYP2D6*4/*10) that were not reported from the previous study (Table 1) . 8 However, the summation of these genotype frequencies with fully functional alleles (CYP2D6*1/*1, CYP2D6*1/*2, and CYP2D6*2/*2) was 15.6%, which agreed with the previous studies. 8, 16 Determination of the CYP2D6*2 allele was useful for separating CYP2D6*2/*10 (EM), CYP2D6*4/*4 (PM), and CYP2D6*4/*10 (IM) from CYP2D6*1/*10 (EM), which was responsible for the low reported prevalence of CYP2D6*1/*10 (15.7%) in this study compared with the previous ones. 8, 16 The CYP2D6*4/*4 and CYP2D6*4/*10 alleles would potentially contribute to the low enzyme activities compared with CYP2D6*10/*10 allele and might differentially affect the concentration of TAM and its metabolites. There were seven patients whose genotypes were classified as CYP2D6*4 instead of CYP2D6*10 according to the simultaneous use of the CYP2D6*2 assay (Table 6 ). Gaedigk et al 26 and Lyon et al 25 suggested that the 100C>T SNP occurred on both the CYP2D6*4 and CYP2D6*10 alleles but they could be assigned during the absence of 1846G>A for the CYP2D6*4 allele. 25, 26 The 1846G>A SNP was not used in this study due to the low prevalence of the CYP2D6*4 allele in Thai population, but the CYP2D6*4 allele was detected in this study by considering the haplotypes of 100C>T with 2850C>T, 25 which were detected by the CYP2D6*10 and CYP2D6*2 assays, respectively. The CYP2D6*2 determination showed the following benefits in this study. First, the CYP2D6*2 assay helped to give a more accurate estimate of the prevalence of the CYP2D6*2 allele by discriminating between CYP2D6*2 and CYP2D6*1, the latter of which is another CYP2D6 wild 
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Charoenchokthavee et al type allele reported in Thai patients. 8 Second, the CYP2D6*2 determination revealed the CYP2D6*2/*10, CYP2D6*4/*4, and CYP2D6*4/*10 genotypes, which have not been discovered by applying only the CYP2D6*10 assay. Third, the CYP2D6*4/*4 and CYP2D6*4/*10 alleles were found in this study, which potentially contributed to the different enzyme activities compared with CYP2D6*1/*10.
The prevalence of CYP2D6*10 was high in Thais, while the prevalence of CYP2D6*4 was high in Caucasians 24 (Table 1) , which subsequently raised CYP2D6*10/*10 to be the most common genotype in this study. This finding disagrees with the study in Caucasians that the CYP2D6*10/*10 allele has not been reported (Table 7) . 24 Moreover, the prevalence of the CYP3A5*1/*3 and CYP3A5*3/*3 alleles was also high in this study (47.8% and 38.8%, respectively) compared with CYP3A5*1/*1 (13.4%), which is in accordance with the previous studies in Caucasian 24 and Asian 14 populations (Tables 1 and  7 ) but disagrees with a previous report that the CYP3A5*1/*1 allele was the most common CYP3A5 genotype in Thai breast cancer patients. 9 This disagreement might reflect the limited number of patients recruited in that study (30 patients) compared with the other studies. 14, 24 Furthermore, the low prevalence of the CYP3A5*1/*1 allele reported in Thai and Asian populations was due to the high prevalence of CYP3A5 polymorphisms in both Caucasians and Asians, including Thais. Moreover, it was found that 20.9% of these patients had only defective alleles, including the two patients who were PM for both CYP2D6 and CYP3A5 genes. Thus, Thai breast cancer patients undergoing TAM treatment potentially have a risk for a low activity of the enzymes involved in the TAM-metabolic pathway, especially for the CYP2D6 and CYP3A5 enzymes that are responsible for END formation.
This study had some limitations. The frequency of the CYP2D6*4 allele was determined by considering the CYP2D6*2 (2850C>T) and CYP2D6*10 (100C>T) haplotypes without using the CYP2D6*4 (1846G>A) assay. According to the reported low prevalence of CYP2D6*4 in Thai breast cancer patients, 8 these genotypes were classified as CYP2D6*2/*10. There were 13 patients (9.7%) who expressed CYP2D6*1/*2 (CYP2D6*2 assay) with CYP2D6*1/*10 (CYP2D6*10 assay) that were possibly carrying CYP2D6*2/*10 (2850C>T and 100C>T were located on different alleles) or CYP2D6*1/*4 (2850C>T and 100C>T were located on the same allele). These genotypes were classified as CYP2D6*2/*10 in this study due to the low prevalence of CYP2D6*4 in Thai patients. 8 However, further investigations need to be performed to explore other possible allele patterns and confirm the genotype classification results of this study.
Conclusion
This research indicated a high prevalence of the CYP2D6 and CYP3A5 defective alleles in Thai breast cancer patients undergoing TAM treatment. Future studies should be focused on the concentration of TAM and its metabolites to reveal the true effect of the enzymes encoded by these gene polymorphisms on TAM treatment, which could be further applied for drug therapy monitoring in clinical settings. 
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